Rani Therapeutics Holdings (RANI) Receivables - Other (2020 - 2024)
Rani Therapeutics Holdings (RANI) posted quarterly Receivables - Other of $428000.0 for Q4 2024, down 75.12% quarter-over-quarter from $1.7 million in Q4 2020.
Rani Therapeutics Holdings (RANI) Receivables - Other (2020 - 2024) Analysis & Trends
Rani Therapeutics Holdings' Receivables - Other history runs 2 years deep, the most recent figure standing at $428000.0 for Q4 2024.
- In Q4 2024, Receivables - Other changed N/A year-over-year to $428000.0; the TTM figure through Dec 2024 stood at $428000.0 (changed N/A YoY), while the FY2024 annual figure was $428000.0, changed N/A from the prior year.
- Receivables - Other for Q4 2024 stood at $428000.0, down from $1.7 million in the prior quarter.
- The five-year high for Receivables - Other was $1.7 million in Q4 2020, with the low at $428000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 428,000.00 |
| Dec 31, 2024 | 428,000.00 |
| Dec 31, 2020 | 1.72 Mn |
| Dec 31, 2020 | 1.72 Mn |